Group One Trading
ZVRA icon

Group One Trading’s Zevra Therapeutics ZVRA Stock Holding History

Group One Trading’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.88M Sell
201,000
-7,400
-4% -$82.3K ﹤0.01% 1875
2026
Q1 		$1.94M Buy
208,400
+112,700
+118% +$1.02M ﹤0.01% 2099
2025
Q4 		$857K Buy
95,700
+19,500
+26% +$184K ﹤0.01% 3036
2025
Q3 		$725K Sell
76,200
-2,400
-3% -$24.1K ﹤0.01% 3328
2025
Q2 		$692K Sell
78,600
-29,100
-27% -$236K ﹤0.01% 3102
2025
Q1 		$807K Buy
107,700
+75,000
+229% +$596K ﹤0.01% 2654
2024
Q4 		$273K Sell
32,700
-282,700
-90% -$2.41M ﹤0.01% 3680
2024
Q3 		$2.19M Buy
315,400
+284,100
+908% +$1.93M 0.01% 1643
2024
Q2 		$153K Sell
31,300
-8,700
-22% -$41.2K ﹤0.01% 3621
2024
Q1 		$232K Buy
40,000
+7,100
+22% +$43.6K ﹤0.01% 3437
2023
Q4 		$215K Sell
32,900
-11,900
-27% -$55.7K ﹤0.01% 3806
2023
Q3 		$216K Sell
44,800
-64,700
-59% -$323K ﹤0.01% 3744
2023
Q2 		$558K Sell
109,500
-14,500
-12% -$78.1K ﹤0.01% 2910
2023
Q1 		$682K Sell
124,000
-301,800
-71% -$1.6M ﹤0.01% 2470
2022
Q4 		$1.95M Sell
425,800
-48,100
-10% -$244K ﹤0.01% 1840
2022
Q3 		$2.96M Sell
473,900
-147,700
-24% -$836K 0.01% 1580
2022
Q2 		$2.77M Buy
621,600
+84,800
+16% +$387K ﹤0.01% 1756
2022
Q1 		$2.7M Sell
536,800
-258,400
-32% -$1.64M ﹤0.01% 2099
2021
Q4 		$6.93M Buy
795,200
+76,900
+11% +$686K 0.01% 1409
2021
Q3 		$6.7M Sell
718,300
-88,300
-11% -$890K 0.01% 1418
2021
Q2 		$10.3M Buy
806,600
+557,300
+224% +$5.99M 0.01% 1054
2021
Q1 		$2.29M Buy
+249,300
New +$2.18M ﹤0.01% 2317
2019
Q2 		– Sell
-163
Closed -$4K – 5459
2019
Q1 		$4K Buy
+163
New +$6K ﹤0.01% 4491
2018
Q3 		– Sell
-69
Closed -$7K – 5672
2018
Q2 		$7K Sell
69
-150
-68% -$14.6K ﹤0.01% 4739
2018
Q1 		$28K Buy
+219
New +$21.2K ﹤0.01% 3949

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Group One Trading's ZVRA Position: Q4 2025 in Review

Group One Trading sold out of Zevra Therapeutics (ZVRA) in Q4 2025, closing a stake of 52,638 shares — an estimated $498K sold.

Group One Trading first reported a position in ZVRA in Q3 2018 and held it in 16 quarters. The position peaked at $501K in Q3 2025. 158 funds tracked by Wall St. Rank hold ZVRA as of Q4 2025.

  • Group One Trading reported no remaining Zevra Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Group One Trading sold 52,638 Zevra Therapeutics shares in Q4 2025, an estimated $498K.
  • Group One Trading first reported a position in Zevra Therapeutics in Q3 2018 and held it in 16 quarters.
  • Group One Trading's Zevra Therapeutics position peaked at $501K in Q3 2025.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2025.

Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.